Cited by 147Cannabis and Cannabinoid ResearchSchizophrenia research and treatmentTryptophan and brain disorders

The DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.

Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol

Gomes, Felipe V., Llorente, Ricardo, Del Bel, Elaine A., Viveros, Maria-Paz, López-Gallardo, Meritxell, Guimarães, Francisco S.·2015·Schizophrenia Research

DOI 10.1016/j.schres.2015.01.015

Open this paper in CoChat — free account

Abstract

NMDA receptor hypofunction could be involved, in addition to the positive, also to the negative symptoms and cognitive deficits found in schizophrenia patients. An increasing number of data has linked schizophrenia with neuroinflammatory conditions and glial cells, such as microglia and astrocytes, have been related to the pathogenesis of schizophrenia. Cannabidiol (CBD), a major non-psychotomimetic constituent of Cannabis sativa with anti-inflammatory and neuroprotective properties induces antipsychotic-like effects. The present study evaluated if repeated treatment with CBD (30 and 60 mg/kg) would attenuate the behavioral and glial changes observed in an animal model of schizophrenia based on the NMDA receptor hypofunction (chronic administration of MK-801, an NMDA receptor antagonist, for 28 days). The behavioral alterations were evaluated in the social interaction and novel object recognition (NOR) tests. These tests have been widely used to study changes related to negative symptoms and cognitive deficits of schizophrenia, respectively. We also evaluated changes in NeuN (a neuronal marker), Iba-1 (a microglia marker) and GFAP (an astrocyte marker) expression in the medial prefrontal cortex (mPFC), dorsal striatum, nucleus accumbens core and shell, and dorsal hippocampus by immunohistochemistry. CBD effects were compared to those induced by the atypical antipsychotic clozapine. Repeated MK-801 administration impaired performance in the social interaction and NOR tests. It also increased the number of GFAP-positive astrocytes in the mPFC and the percentage of Iba-1-positive microglia cells with a reactive phenotype in the mPFC and dorsal hippocampus without changing the number of Iba-1-positive cells. No change in the number of NeuN-positive cells was observed. Both the behavioral disruptions and the changes in expression of glial markers induced by MK-801 treatment were attenuated by repeated treatment with CBD or clozapine. These data reinforces the proposal that CBD may induce antipsychotic-like effects. Although the possible mechanism of action of these effects is still unknown, it may involve CBD anti-inflammatory and neuroprotective properties. Furthermore, our data support the view that inhibition of microglial activation may improve schizophrenia symptoms.

Integrity signals

Registry

Crossref · 10.1016/j.schres.2015.01.015

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The mouse brain in stereotaxic coordinates
Konsman, J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00088-x · Cited by 16,796
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat
Hoover, W. B., & Vertes, R. P. (2007) · Brain Structure and Function · doi:10.1007/s00429-007-0150-4 · Cited by 1,365
The Neuropsychopharmacology of Phencyclidine From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia
Jentsch, J. D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,329
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,230
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on
Carobrez, A. P., & Bertoglio, L. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.017 · Cited by 993
Microglia: Scapegoat, saboteur, or something else?
Aguzzi, A., Barres, B. A., & Bennett, M. L. (2013) · Science · doi:10.1126/science.1227901 · Cited by 836
Cognitive Impairment in Schizophrenia Is the Core of the Disorder
Elvevag, B., & Goldberg, T. E. (2000) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v14.i1.10 · Cited by 835 · cited 2×
“br long-term outcome (Elvevag and Goldberg, 2000; Lesh et al., 2011).”
Background
Heterogeneity of astrocytic form and function.
Oberheim, N. A., Goldman, S. A., & Nedergaard, M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-452-0_3 · Cited by 638
Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia
Fillman, S. G., Cloonan, N., Catts, V. S., Miller, L. C., Wong, J., McCrossin, T., Cairns, M., & Weickert, C. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.110 · Cited by 609
Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study
van Berckel, B. N. M., Bossong, M. G., Boellaard, R., Kloet, R. W., Schuitemaker, A., Caspers, E., Luurtsema, G., Windhorst, A. D., Cahn, W., Lammertsma, A. A., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.025 · Cited by 582
Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study
Doorduin, J., de Vries, E. F. J., Willemsen, A. T. M., de Groot, J. C., Dierckx, R., & Klein, H. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066647 · Cited by 561
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M., & Carter, C. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 522
GABAergic interneuron origin of schizophrenia pathophysiology
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., & Belforte, J. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.022 · Cited by 498
NMDA Receptor Hypofunction, Parvalbumin-Positive Neurons, and Cortical Gamma Oscillations in Schizophrenia
Gonzalez-Burgos, G., & Lewis, D. A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs010 · Cited by 478
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475
Self-citation
Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer’s Disease
Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071290 · Cited by 410
Role of microglia in CNS inflammation
Graeber, M. B., Li, W., & Rodriguez, M. L. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.033 · Cited by 392 · cited 3×
“Microglia and astrocytes are the major immune cells in the central nervous system (CNS), regulating the induction as well as the limitation of inflammatory processes (Sofroniew and Vinters, 2010; Graeber et al., 2011).”
Background
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
Neuroinflammation and regulation of glial glutamate uptake in neurological disorders
Tilleux, S., & Hermans, E. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21325 · Cited by 381
Increase in HLA-DR Immunoreactive Microglia in Frontal and Temporal Cortex of Chronic Schizophrenics
Radewicz, K., Garey, L. J., Gentleman, S. M., & Reynolds, R. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.2.137 · Cited by 341
Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function
Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., & D’Souza, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.985 · Cited by 317
Neuroinflammation in schizophrenia especially focused on the role of microglia
Monji, A., Kato, T. A., Mizoguchi, Y., Horikawa, H., Seki, Y., Kasai, M., Yamauchi, Y., Yamada, S., & Kanba, S. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.002 · Cited by 314
Cannabidiol in vivo blunts β‐amyloid induced neuroinflammation by suppressing IL‐1β and iNOS expression
Esposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707337 · Cited by 308
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
Mecha, M., Feliú, A., Iñigo, P. M., Mestre, L., Carrillo-Salinas, F. J., & Guaza, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.06.016 · Cited by 285
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
Chaudhry, I. B., Hallak, J. E. C., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S. M., Dunn, G., & Deakin, J. F. W. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444941 · Cited by 284
Phencyclidine animal models of schizophrenia: Approaches from abnormality of glutamatergic neurotransmission and neurodevelopment
Mouri, A., Noda, Y., Enomoto, T., & Nabeshima, T. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.019 · Cited by 267
Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders
Laan, W., Grobbee, D. E., Selten, J., Heijnen, C. J., Kahn, R. S., & Burger, H. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05117yel · Cited by 265
Role of Astrocytes in Brain Function and Disease
Sidoryk‐Wȩgrzynowicz, M., Węgrzynowicz, M., Lee, E.-S., Bowman, A. B., & Aschner, M. (2010) · Toxicologic Pathology · doi:10.1177/0192623310385254 · Cited by 265
Antipsychotic effect of cannabidiol.
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264
Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Möller, H., Klauß, V., Schwarz, M., & Riedel, M. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.015 · Cited by 252
Prenatal stress causes alterations in the morphology of microglia and the inflammatory response of the hippocampus of adult female mice
Diz-Chaves, Y., Pernía, O., Carrero, P., & García‐Segura, L. M. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-71 · Cited by 243
A Pharmacological Model for Psychosis Based on N-methyl-D-aspartate Receptor Hypofunction: Molecular, Cellular, Functional and Behavioral Abnormalities
Rujescu, D., Bender, A., Keck, M. E., Hartmann, A. M., Ohl, F., Ræder, H., Giegling, I., Genius, J., McCarley, R. W., Möller, H., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.029 · Cited by 241
Animal models for the negative symptoms of schizophrenia
Ellenbroek, B. A., & Cools, A. R. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00006 · Cited by 198
Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia
Rajkowska, G., Miguel-Hidalgo, J. J., Makkos, Z., Meltzer, H. Y., Overholser, J. C., & Stockmeier, C. A. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00339-0 · Cited by 196
Cannabidiol monotherapy for treatment-resistant schizophrenia
Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192
The Novel Object Recognition Test in Rodents in Relation to Cognitive Impairment in Schizophrenia
Rajagopal, L., Massey, B. W., Huang, M., Oyamada, Y., & Meltzer, H. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131216114240 · Cited by 173
Functions of microglia in the central nervous system—beyond the immune response
Wake, H., Moorhouse, A. J., & Nabekura, J. (2011) · Neuron Glia Biology · doi:10.1017/s1740925x12000063 · Cited by 167
Subchronic Phencyclidine Administration Increases Mesolimbic Dopaminergic System Responsivity and Augments Stress- and Psychostimulant-Induced Hyperlocomotion
Jentsch, D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00004-9 · Cited by 166
The object recognition task in rats and mice: A simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity
Bertaina‐Anglade, V., Enjuanes, E., Morillon, D., & Rochelle, C. D. L. (2006) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2006.04.001 · Cited by 165
The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-γ
Bian, Q., Kato, T. A., Monji, A., Hashioka, S., Mizoguchi, Y., Horikawa, H., & Kanba, S. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.06.031 · Cited by 155
Hypothalamic-Pituitary-Adrenal Axis Dysfunction and Illness Progression in Bipolar Disorder
Fries, G. R., Vasconcelos-Moreno, M. P., Gubert, C., Santos, B. T. M. Q. D., Sartori, J., Eisele, B. S., Ferrari, P., Fijtman, A., Rüegg, J., Gassen, N. C., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu043 · Cited by 153
Increased expression of astrocyte markers in schizophrenia: Association with neuroinflammation
Catts, V. S., Wong, J., Fillman, S. G., Fung, S. J., & Weickert, C. S. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414531078 · Cited by 148
Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: Reversal by clozapine
Ribeiro, B. M. M., do Carmo, M. R. S., Freire, R. S., Rocha, N. F. M., Borella, V., Menezes, A. T., Monte, A. S., Gomes, P. X. L., de Sousa, F. C. F., Vale, M. L., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.040 · Cited by 124
Searching for Neuropathology: Gliosis in Schizophrenia
Schnieder, T. P., & Dwork, A. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.027 · Cited by 108
Protective Effects of Cannabidiol Against Hippocampal Cell Death and Cognitive Impairment Induced by Bilateral Common Carotid Artery Occlusion in Mice
Schiavon, A. P., Soares, L. M., Bonato, J. M., Milani, H., Guimarães, F. S., & de Oliveira, R. M. W. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9457-0 · Cited by 100
Clozapine Protects Dopaminergic Neurons from Inflammation-Induced Damage by Inhibiting Microglial Overactivation
Hu, X., Zhou, H., Zhang, D., Yang, S., Li, Q., Wu, H.-M., Chen, P.-S., Wilson, B. C., Gao, H., Lu, R., et al. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9309-0 · Cited by 100
Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia
Viganò, D., Guidali, C., Petrosino, S., Realini, N., Rubino, T., Marzo, V. D., & Parolaro, D. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009371 · Cited by 99
Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness
Feresten, A. H., Barakauskas, V., Ypsilanti, A. R., Barr, A. M., & Beasley, C. L. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.024 · Cited by 90
Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice
Gomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89
MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning
Wozniak, D. F., Brosnan-Watters, G., Nardi, A. M. D., McEwen, M. L., Corso, T. D., Olney, J. W., & Fix, A. S. (1996) · Brain Research · doi:10.1016/0006-8993(95)01230-3 · Cited by 87
Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
Ribeiro-Santos, R., Teixeira, A. L., & Salgado, J. V. (2014) · Current Neuropharmacology · doi:10.2174/1570159x1203140511160832 · Cited by 86
CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice
López-Rodríguez, A. B., Siopi, E., Finn, D. P., Marchand‐Leroux, C., García‐Segura, L. M., Jafarian-Tehrani, M., & Viveros, M. (2013) · Cerebral Cortex · doi:10.1093/cercor/bht202 · Cited by 85
Cerebellar toxicity of phencyclidine
Näkki, R., Koıstınaho, J., Sharp, F. R., & Sagar, S. M. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-03-02097.1995 · Cited by 68
Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia
Hanson, E., Healey, K. M., Wolf, D. H., & Kohler, C. G. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0148-0 · Cited by 61
Haloperidol Prevents Ketamine- and Phencyclidine-Induced HSP70 Protein Expression but Not Microglial Activation
Näkki, R., Nickolenko, J., Chang, J., Sagar, S. M., & Sharp, F. R. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0022 · Cited by 60
Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine
Guidali, C., Viganò, D., Petrosino, S., Zamberletti, E., Realini, N., Binelli, G., Rubino, T., Marzo, V. D., & Parolaro, D. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000209 · Cited by 56
S100B in schizophrenia: an update.
Rothermundt, M., Ahn, J. N., & Jörgens, S. (2009) · PubMed · Cited by 51
Pharmacological blockade of either cannabinoid CB1 or CB2 receptors prevents both cocaine-induced conditioned locomotion and cocaine-induced reduction of cell proliferation in the hippocampus of adult male rat
Blanco, E., Rivera, P., Arrabal, S., Vargas, A., Pavón, F. J., Serrano, A., Castilla‐Ortega, E., Galeano, P., Rubio, L., Suárez, J., et al. (2014) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00106 · Cited by 50
Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats
Perez, M., Ulian-Benitez, S., Cartarozzi, L. P., Bel, E. A. D., Guimarães, F. S., & de Oliveira, A. L. R. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12341 · Cited by 49
Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia
Xia, M., Abazyan, S., Jouroukhin, Y., & Pletnikov, M. V. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.10.044 · Cited by 46
Astrocytes as Active Participants of Glutamatergic Function and Regulators of its Homeostasis
Bezzi, P., Vesce, S., Panzarasa, P., & Volterra, A. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4685-6_6 · Cited by 40
Stereological assessment of the dorsal anterior cingulate cortex in schizophrenia: absence of changes in neuronal and glial densities
Höistad, M., Heinsen, H., Wicinski, B. A., Schmitz, C., & Hof, P. R. (2012) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01296.x · Cited by 32
Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801-treated rat brain regions
Arif, M., Chikuma, T., Ahmed, M. M., Yoshida, S., & Kato, T. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.10.021 · Cited by 32
Neural and astroglial effects of a chronic parachlorophenylalanine-induced serotonin synthesis inhibition
Tagliaferro, P. A., Ramos, A. J., López, E. M., Saavedra, J. P., & Brusco, A. (1997) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815176 · Cited by 31
Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis
Genius, J., Benninghoff, J., Reuter, N., Braun, I., Giegling, I., Hartmann, A. M., Möller, H., & Rujescu, D. (2012) · Methods · doi:10.1016/j.ymeth.2012.04.002 · Cited by 12
Untitled work
(1997) · doi:10.1002/(sici)1098-1063(1997)7:4

Sorted by citations

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
McCutcheon, R. A., Keefe, R. S. E., & McGuire, P. K. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01949-9 · Cited by 861
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 664
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306

See all 147

Authors: Gomes, F. V., Llorente, R., Del Bel, E. A., Viveros, M.-P., López-Gallardo, M., & Guimarães, F. S.
Affiliations: Universidade de São Paulo (BR)
Universidad Complutense de Madrid (ES)
ORCID: Gomes, Felipe V.
Llorente, Ricardo
Guimarães, Francisco S.
Venue: Schizophrenia Research
Publisher: Elsevier BV
Published: 2015-05
Volume: 164
Issue: 1-3
Pages: 155-163
ISSN: 0920-9964 (ISSN-L)
DOI: 10.1016/j.schres.2015.01.015
OpenAlex: W2028951205
Cited by: 147
References: 72
Citations by year: 2026: 4 · 2025: 13 · 2024: 15 · 2023: 8 · 2022: 13 · 2021: 24 · 2020: 11 · 2019: 14 · 2018: 15 · 2017: 14 · 2016: 12 · 2015: 4
FWCI: 10.86
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Schizophrenia Research (publishedVersion)
PubMed (publishedVersion)
Library Open Repository (Universidad Complutense Madrid) (submittedVersion)
Funders: FAPESP (012/17626-7)
CNPq (470311/2012-6)
Instituto de Salud Carlos III, Redes temáticas de Investigación Cooperativa en salud (RD2012/0028/0021)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: cannabidiol, schizophrenia
MeSH terms: Animals, Brain, Calcium-Binding Proteins, Cannabidiol, Clozapine, Disease Models, Animal, Dose-Response Relationship, Drug, Exploratory Behavior, Gene Expression Regulation, Glial Fibrillary Acidic Protein, Male, Mice, Inbred C57BL, Microfilament Proteins, Neuroglia, Phosphopyruvate Hydratase, Psychotic Disorders, Antipsychotic Agents, Dizocilpine Maleate, Excitatory Amino Acid Antagonists, Maze Learning, Recognition, Psychology, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks